|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
4
|
|
pubmed:dateCreated |
1990-11-1
|
|
pubmed:abstractText |
To study the effects of localized secretion of cytokines on tumor progression, the gene for human interleukin 2 (IL-2) was introduced via retroviral vectors into CMS-5 cells, a weakly immunogenic mouse fibrosarcoma cell line of BALB/c origin. Secretion of low levels of IL-2 from the tumor cells abrogated their tumorigenicity and induced a long-lasting protective immune response against a challenge with a tumorigenic dose of parental CMS-5 cells. Co-injection of IL-2-producing CMS-5 cells with unmodified tumor cells inhibited tumor formation even when highly tumorigenic doses of CMS-5 cells were used. Cytolytic activity in mice injected with parental CMS-5 cells was transient and was greatly diminished 3 wk after injection, as commonly observed in tumor-bearing animals. However, in mice injected with IL-2-producing cells, tumor-specific cytolytic activity persisted at high levels for the duration of the observation period (at least 75 d). High levels of tumor-specific cytolytic activity could also be detected in parental CMS-5 tumor-bearing animals 18 d after inoculation with tumor cells, if IL-2-producing CMS-5 cells but not unmodified parental tumor cells were used as targets. These studies highlight the potential advantages of localized secretion of cytokines mediated via gene transfer to induce potent anti-tumor immune responses.
|
|
pubmed:commentsCorrections |
http://linkedlifedata.com/resource/pubmed/commentcorrection/2212951-13116120,
http://linkedlifedata.com/resource/pubmed/commentcorrection/2212951-13502695,
http://linkedlifedata.com/resource/pubmed/commentcorrection/2212951-197192,
http://linkedlifedata.com/resource/pubmed/commentcorrection/2212951-2137372,
http://linkedlifedata.com/resource/pubmed/commentcorrection/2212951-2462307,
http://linkedlifedata.com/resource/pubmed/commentcorrection/2212951-2512580,
http://linkedlifedata.com/resource/pubmed/commentcorrection/2212951-2542934,
http://linkedlifedata.com/resource/pubmed/commentcorrection/2212951-2683611,
http://linkedlifedata.com/resource/pubmed/commentcorrection/2212951-2738408,
http://linkedlifedata.com/resource/pubmed/commentcorrection/2212951-2785856,
http://linkedlifedata.com/resource/pubmed/commentcorrection/2212951-2831375,
http://linkedlifedata.com/resource/pubmed/commentcorrection/2212951-2974763,
http://linkedlifedata.com/resource/pubmed/commentcorrection/2212951-3033290,
http://linkedlifedata.com/resource/pubmed/commentcorrection/2212951-3114593,
http://linkedlifedata.com/resource/pubmed/commentcorrection/2212951-3261761,
http://linkedlifedata.com/resource/pubmed/commentcorrection/2212951-3265909,
http://linkedlifedata.com/resource/pubmed/commentcorrection/2212951-3458189,
http://linkedlifedata.com/resource/pubmed/commentcorrection/2212951-3491145,
http://linkedlifedata.com/resource/pubmed/commentcorrection/2212951-3518753,
http://linkedlifedata.com/resource/pubmed/commentcorrection/2212951-382778,
http://linkedlifedata.com/resource/pubmed/commentcorrection/2212951-3871453,
http://linkedlifedata.com/resource/pubmed/commentcorrection/2212951-3886826,
http://linkedlifedata.com/resource/pubmed/commentcorrection/2212951-6258156,
http://linkedlifedata.com/resource/pubmed/commentcorrection/2212951-6352804,
http://linkedlifedata.com/resource/pubmed/commentcorrection/2212951-6481400,
http://linkedlifedata.com/resource/pubmed/commentcorrection/2212951-65423,
http://linkedlifedata.com/resource/pubmed/commentcorrection/2212951-6607956,
http://linkedlifedata.com/resource/pubmed/commentcorrection/2212951-6726280,
http://linkedlifedata.com/resource/pubmed/commentcorrection/2212951-68658,
http://linkedlifedata.com/resource/pubmed/commentcorrection/2212951-6977616,
http://linkedlifedata.com/resource/pubmed/commentcorrection/2212951-6978875,
http://linkedlifedata.com/resource/pubmed/commentcorrection/2212951-773395,
http://linkedlifedata.com/resource/pubmed/commentcorrection/2212951-814160
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Oct
|
|
pubmed:issn |
0022-1007
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:day |
1
|
|
pubmed:volume |
172
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
1217-24
|
|
pubmed:dateRevised |
2009-11-18
|
|
pubmed:meshHeading |
pubmed-meshheading:2212951-Animals,
pubmed-meshheading:2212951-Cytotoxicity, Immunologic,
pubmed-meshheading:2212951-Humans,
pubmed-meshheading:2212951-Interleukin-2,
pubmed-meshheading:2212951-Mice,
pubmed-meshheading:2212951-Mice, Inbred BALB C,
pubmed-meshheading:2212951-Neoplasms, Experimental,
pubmed-meshheading:2212951-T-Lymphocytes, Cytotoxic,
pubmed-meshheading:2212951-Transfection,
pubmed-meshheading:2212951-Tumor Cells, Cultured
|
|
pubmed:year |
1990
|
|
pubmed:articleTitle |
Interleukin 2 gene transfer into tumor cells abrogates tumorigenicity and induces protective immunity.
|
|
pubmed:affiliation |
Department of Hematology/Lymphoma, Memorial-Sloan Kettering Cancer Center, New York, New York 10021.
|
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|
